Use of ACE Inhibitors in Pregnant Women and the Risk of Congenital Heart Defects De-Kun Li, MD, PhD Division of Research Kaiser Permanente Northern California.

Slides:

Advertisements

Similar presentations

Presented by: National Forum for Heart Disease and Stroke Prevention Improving Hypertension Control The Kaiser Permanente Hypertension Control Project:

Advertisements

Perinatal Health in Canada: An Overview K.S. Joseph MD, PhD Canadian Perinatal Surveillance System.

Intimate Partner Violence (IPV) and Women’s Health during Pregnancy Findings from the Rhode Island PRAMS Hanna Kim, Samara Viner-Brown, Rachel.

The Forgotten Beneficiary of the Medicaid Expansions Andrea Kutinova and Karen Smith Conway Department of Economics University of New Hampshire.

Associations between Obesity and Depression by Race/Ethnicity and Education among Women: Results from the National Health and Nutrition Examination Survey,

Case-Control Studies (Retrospective Studies). What is a cohort?

1 Case-Control Study Design Two groups are selected, one of people with the disease (cases), and the other of people with the same general characteristics.

Congenital malformations and birth weight: a family perspective Dr. Kari K.Melve Department of Public Health & Primary Health Care University of Bergen,

Outcome of diabetic pregnancy Comparison of North East England with Norway December 2000 Gillian Hawthorne.

Gestational diabetes mellitus (GDM), a common medical complication of pregnancy, is defined as “any degree of glucose intolerance with onset or first.

Journal Club Alcohol and Health: Current Evidence May-June 2006.

RACIAL DISPARITIES IN PRESCRIPTION DRUG UTILIZATION AN ANALYSIS OF BETA-BLOCKER AND STATIN USE FOLLOWING HOSPITALIZATION FOR ACUTE MYOCARDIAL INFARCTION.

Guidance for Industry Establishing Pregnancy Registries Pregnancy Registry Working Group Pregnancy Labeling Taskforce March, 2000 Evelyn M. Rodriguez M.D.,

Manish Chaudhary BPH, MPH

Principles of Epidemiology Lecture 9 Dona Schneider, PhD, MPH, FACE

The Association between Antenatal Depression and Adverse Birth Outcomes among Women Receiving Medicaid in Washington State Amelia R. Gavin, PhD School.

Asthma and Pregnancy Michael Schatz, MD, MS Chief, Department of Allergy Kaiser-Permanente Medical Center San Diego, CA.

THE PREVALENCE AND PREDICTORS OF LOW-COST GENERIC PROGRAM USE IN A NATIONALLY REPRESENTATIVE ADULT POPULATION: IMPLICATIONS FOR PATIENTS, RESEARCH, AND.

1 Lecture 20: Non-experimental studies of interventions Describe the levels of evaluation (structure, process, outcome) and give examples of measures of.

ILLNESSES, INJURIES, AND HOSPITALIZATIONS AMONG INNER-CITY MINORITY INFANTS IN CHICAGO.

Dental Care During Pregnancy Oregon 2000 Kathy R. Phipps, DrPH (1) Kenneth D. Rosenberg, MD, MPH (2) Alfredo P. Sandoval, MS, MBA (2) (1) Association of.

TRANSLATING VISITS INTO PATIENTS USING AMBULATORY VISIT DATA (Hypertensive patient case study) by Esther Hing, M.P.H. and Julia Holmes, Ph.D U.S. DEPARTMENT.

Health Disparities of Minority Women and Diabetes Kathleen M. Rayman, Ph.D., RN Appalachian Center for Translational Research in Disparities Faculty Development.

Reduced Risks of Neural Tube Defects and Orofacial Clefts With Higher Diet Quality Carmichael SL, Yang W, Feldkamp ML, et al; National Birth Defects Prevention.

OBesity Project Pregnancy.

Prevention of mother to child transmission of viral hepatitis Dr. Lawrence Mbuagbaw MD, MPH, PhD, FRSPH 2nd International HIV/Viral Hepatitis Co-infection.

Racial Disparity in Correlates of Late Preterm Births: A Population-Based Study Shailja Jakhar, Christine Williams, Louis Flick, Jen Jen Chang, Qian Min,

Population attributable risks for low birth weight among singleton births—Colorado, Ashley Juhl, MSPH Epidemiology, Planning and Evaluation Branch.

CHP400: Community Health Program- lI Research Methodology STUDY DESIGNS Observational / Analytical Studies Case Control Studies Present: Disease Past:

Washington D.C., USA, JULY Rulin C. Hechter 1 MD,PhD Jean Q. Wang 1 PhD Margo A. Sidell 1 ScD William J. Towner 2 MD 1 Dept.

Peter Emery, MD Specialist in Clinical Hypertension InterMed Portland, ME.

Observation Bias (Information Bias) Biased measure of association due to incorrect categorization. DiseasedNot Diseased Exposed Not Exposed The Correct.

LOGO National Research Institute for Family Planning Preconception Blood Pressure and Risk of Preterm delivery in Chinese reproductive age women Yang Y,

CHAPTER-SPECIFIC GUIDELINES (ICD-10-CM CHAPTERS 15-21)

Mother and Child Health: Research Methods G.J.Ebrahim Editor Journal of Tropical Pediatrics, Oxford University Press.

Disease Burden, Utilization and Costs of Care Among Women Using Veterans Health Administration HERC Cyber Seminar May 25, 2005 Presented by Ciaran Phibbs.

Population-Based Epidemiologic Safety Studies: Overview and Challenges Drug Safety and Risk Management Advisory Committee Silver Spring, Maryland June.

Joint Dermatologic and Ophthalmic Drugs & Drug Safety and Risk Management Advisory Committee February 26 & 27, 2004 RISK MANAGEMENT OPTIONS FOR PREGNANCY.

Case-control study Chihaya Koriyama August 17 (Lecture 1)

Measures of Association Intermediate Epidemiology.

Use of Fan During Sleep and the Risk of Sudden Infant Death Syndrome De-Kun Li, MD, PhD Division of Research Kaiser Permanente Oakland, California March.

Drug Safety and Risk Management Advisory Committee May 18-19, Overview of Drug Safety Challenges Gerald J. Dal Pan, MD, MHS Director Division of.

LEADING RESEARCH… MEASURES THAT COUNT Challenges of Studying Cardiovascular Outcomes in ADHD Elizabeth B. Andrews, MPH, PhD, VP, Pharmacoepidemiology and.

Types of study designs.

Overview of Study Designs. Study Designs Experimental Randomized Controlled Trial Group Randomized Trial Observational Descriptive Analytical Cross-sectional.

Copyright © 2012, 2011, 2010, 2009, 2008, 2007, 2006, 2005, 2004, 2002 by Saunders, an imprint of Elsevier Inc. Slide 1 CHAPTER 7 CHAPTER-SPECIFIC GUIDELINES.

A Claims Database Approach to Evaluating Cardiovascular Safety of ADHD Medications A. J. Allen, M.D., Ph.D. Child Psychiatrist, Pharmacologist Global Medical.

The Impact of Birth Spacing on Subsequent Feto-Infant Outcomes among Community Enrollees of a Federal Healthy Start Project Hamisu M. Salihu, MD, PhD Euna.

Matching. Objectives Discuss methods of matching Discuss advantages and disadvantages of matching Discuss applications of matching Confounding residual.

Odds Ratio& Bias in case-control studies

Cohort Studies Dr Hayfa Wahbi, Dr. Amna Rehana Siddiqui & Department of Family & Community Medicine September 2015.

ЗДОРОВЪЕ SHENDET здоров'я ЗДРАВЉЕ ZDRAWIE ZDRAVLJE ZDRAVÍ ЗДОРОВЪЕ Pregnancy Outcomes Among Immigrant Women from Eastern Europe and the CIS in New York.

National Center for Chronic Disease Prevention and Health Promotion Centers for Disease Control and Prevention *The findings and conclusions in this presentation.

Racial/Ethnic Disparities in Gestational Diabetes Mellitus in Oregon Monica Hunsberger, MPH, RD, PhD 1, Rebecca J. Donatelle, PhD 2, Kenneth D. Rosenberg,

Case Control study. An investigation that compares a group of people with a disease to a group of people without the disease. Used to identify and assess.

Measures of disease frequency Simon Thornley. Measures of Effect and Disease Frequency Aims – To define and describe the uses of common epidemiological.

Explaining the Infant Mortality Increase Marian MacDorman, Joyce Martin, T.J.Mathews, Donna Hoyert, and Stephanie Ventura Division of Vital Statistics.

Use of Acyclovir, Valacyclovir, and Famciclovir in the First Trimester of Pregnancy and the Risk of Birth Defects Björn Pasternak; Anders Hviid R3 Jungwook.

Chapter 9: Case Control Studies Objectives: -List advantages and disadvantages of case-control studies -Identify how selection and information bias can.

Association Between Serotonergic Antidepressant Use During Pregnancy and Autism Spectrum Disorder in Children Hilary K. Brown, PhD; Joel G. Ray, MD, MSc,

Associations of Maternal Antidepressant Use During the First Trimester of Pregnancy With Preterm Birth, Small for Gestational Age, Autism Spectrum Disorder,

Age at First Measles-Mumps-Rubella Vaccination in Children with Autism and School-Matched Control Subjects William W. Thompson, PhD Presented at the.

Birth by the Numbers Gene Declercq March, 2016

Introduction Materials and Methods Results Conclusions

Bronx Community Health Dashboard: Maternal and Child Health Last Updated: 1/31/2018 See last slide for more information about this project.

Adele Schwartz Benzaken

Risk of major congenital malformations among study infants according to fetal exposure to antihypertensives during first trimester alone* Variable ACE.

Chantal Nelson BORN Annual Conference April 25, 2017

Presentation transcript:

Use of ACE Inhibitors in Pregnant Women and the Risk of Congenital Heart Defects De-Kun Li, MD, PhD Division of Research Kaiser Permanente Northern California Oakland, California Sponsored by AHRQ DEcIDE TO HHSA I -TO3-WA1

Background (ACEIs): a class of antihypertensive medications Angiotensin-converting enzyme inhibitors (ACEIs): a class of antihypertensive medications Widely used for hypertension treatment Hypertension in pregnancy: 5-10%

Background Fetal toxicity for use of ACEIs in the 2 nd or 3 rd trimester – –Oligohydramnios – –Fetal growth retardation – –Pulmonary hypoplasia – –Hypocalvaria – –Neonatal hypotension – –Renal failure – –High mortality Hypotension related

Background A new study linked ACEI use in the 1 st trimester to birth defects (BD) –Increased risk of BDs with ACEI use (RR: 2.7 to 4.4) –No increased risk of BDs with use of other antihypertensives (RR: 0.6 to 0.9) –Compared to all non-users –The increased risk unique to ACEI users

Study Objectives To replicate the new study finding in a larger and diverse population Does use of ACEIs during 1 st trimester increase the risk of birth defects, especially heart defects and NTDs? Does timing of the exposure matter? Is the association unique to ACEI use or to all antihypertensive medications? Is the medication or hypertension?

Study Population: Kaiser Permanente Northern California (KPNC) 3.2 million members Diverse, representative population Annual births: 32,000-34,000 –Gestational age recorded –Able to determine gestational age at drug use –Identify pregnancy and labor complications (e.g., PE, PROM, diabetes, infections, fetal distress, placenta previa, abruptio placenta, and seizure)

KPNC Pregnancy & Birth Data Diabetes registry Diagnosis of birth defects and other medical conditions in newborns Regionwide data going back to 1995

KPNC: Drug Exposure Data All ordered and dispensed ambulatory prescription medications since 1995 Information on estimated days supply and refill dates/patterns Some OTC medications

KPNC: Clinical and Admin Databases Indications and other confounders –Clinical diagnoses (inpatient and ambulatory) –Laboratory test results –Multiple, validated disease registries: diabetes registry, asthma registry, cancer registry, etc –Ability to link to birth certificate info –Access to maternal weight or BMI EMR in recent years

Study Design Population-based cohort study of pregnant women Linkage across clinical diagnosis data, outpatient pharmacy data, laboratory results, and birth certificate data

Exposed Cohort Pregnant women exposed to ACE inhibitors –Any time during pregnancy –During the first trimester –During the second and third trimesters –During multiple trimesters

Unexposed Cohorts Three types of comparison groups (controls) –Users of other antihypertensive medications during pregnancy –Pregnant women with a diagnosis of hypertension, but no use of antihypertensives –Pregnant women without a diagnosis of hypertension and use of any antihypertensive medications during pregnancy

Primary Outcome Measures Live birth –Birth defects Overall birth defects Overall birth defects Congenital heart defects Congenital heart defects Neural tube defects Neural tube defects

Linkage Process (1): All livebirths Identify all live births (birth cohort) Determine their gestational age Determine birth type (live vs. still birth)

Linkage Process (2): Identifying Women Exposed to ACEIs and Other drugs Determine a cohort of medication users –Identify female users of ACEIs during the study period ( ) –Identify female users of other antihypertensive medications during the same study period

Linkage Process (3): Characterizing Drug Exposure among Mothers of liveborns Linkage between birth cohort and the cohort of medication users Determine use of ACEI during pregnancy Determine the timing of ACEI exposure Determine use of other antihypertensive medications

Linkage Process (4): Identifying Potential Confounders Linkage to other data sources –Birth Certificates –Other maternal clinical data for weight or BMI –Gestational Diabetes Registry –Clinical data for diagnosis of hypertension

Linkage Process (5): Identifying Birth Defects in Pregnancies >20 Weeks Identify birth defects up to 13 years of age Verify diagnoses of birth defects among a random sample of those with birth defects –Over-sample those with exposure to ACE inhibitors

Results More than More than 465,816 mother-infant pairs Prevalence of ACEI use: – –1.8/1,000 any time during pregnancy – –1.0/1,000 during the first trimester – –0.1/1,000 in the 2 nd or 3 rd trimester Prevalence of other antihypertensive –38/1,00 during pregnancy –3.0/1,000 during the first trimester only – –28.5/1,000 in the 2 nd or 3 rd trimester

Table 1. Distribution of Selected Maternal Characteristics by Fetal Exposure Status to Antihypertensive Medications during Pregnancy, Kaiser Permanente of Northern California Characteristics Antihypertensive Medication Use No Meds, No HTN a (N=416,218) No Meds, HTN b (N=31,274) Other Meds c (N=17,507) ACEI(N=817) Maternal Age at Delivery (yr) <20 27,839 (6.7%) 2,019 (6.5%) 899 (5.1%) 7 (0.9%) 20-<25 73,186 (17.6%) 5,210 (16.7%) 2,340 (13.4%) 46 (5.6%) 25-<30 119,109 (28.6%) 8,124 (26.0%) 4,289 (24.5%) 109 (13.3%) 30-<35 118,237 (28.4%) 8,648 (27.7%) 5,113 (29.2%) 231 (28.3%) 35-<40 62,812 (15.1%) 5,554 (17.8%) 3,647 (20.8%) 269 (32.9%) ,523 (3.5%) 1,710 (5.5%) 1,204 (6.9%) 154 (18.9%) Unknown 512 (0.1%) 9 (0.0%) 15 (0.1%) 1 (0.1%) Maternal Race/Ethnicity White 185,778 (44.6%) 15,286 (48.9%) 8,139 (46.5%) 282 (34.5%) African American 34,988 (8.4%) 3,471 (11.1%) 2,473 (14.1%) 163 (20.0%) Hispanic 89,377 (21.5%) 6,179 (19.8%) 2,833 (16.2%) 135 (16.5%) Asian 84,594 (20.3%) 5,143 (16.4%) 3,286 (18.8%) 175 (21.4%) Other 3,477 (0.8%) 313 (1.0%) 195 (1.1%) 9 (1.1%) Unknown 18,004 (4.3%) 882 (2.8%) 581 (3.3%) 53 (6.5%)

Table 1. Distribution of Selected Maternal Characteristics by Fetal Exposure Status to Antihypertensive Medications during Pregnancy, Kaiser Permanente of Northern California (Cont.) Characteristics Antihypertensive Medication Use No Meds, No HTN a (N=416,218) No Meds, HTN b (N=31,274) Other Meds c (N=17,507) ACEI(N=817) Parity (Previous Live Births) 0 161,182 (38.7%) 15,642 (50.0%) 6,319 (36.1%) 213 (26.1%) 1 135,153 (32.5%) 8,560 (27.4%) 5,373 (30.7%) 212 (26.0%) 2 65,195 (15.7%) 3,842 (12.3%) 3,046 (17.4%) 181 (22.2%) 3+ 35,375 (8.5%) 2,227 (7.1%) 1,952 (11.2%) 143 (17.5%) Unknown 19,313 (4.6%) 1,003 (3.2%) 817 (4.7%) 68 (8.3%) Maternal Weight <90 th Percentile 263,013 (63.2%) 17,377 (55.6%) 10,220 (58.4%) 350 (42.8%) ≥90 th Percentile (207 lbs) 25,723 (6.2%) 5,736 (18.3%) 2,229 (12.7%) 235 (28.8%) Unknown 127,482 (30.6%) 8,161 (26.1%) 5,058 (28.9%) 232 (28.4%) Pre-existing Diabetes Yes 1,651 (0.4%) 689 (2.2%) 470 (2.7%) 316 (38.7%) No 414,567 (99.6%) 30,585 (97.8%) 17,037 (97.3%) 501 (61.3%) a. No use of anti-hypertensive medications during pregnancy and no diagnosis of hypertension b. No use of anti-hypertensive medications during pregnancy, but with a diagnosis of hypertension c. Anti-hypertensive medications other than ACE inhibitors (ACEI)

Table 2. Fetal Exposure to Antihypertensive Medications and the Risk of Major Malformations, Kaiser Permanente, Northern California Medication use Birth Defects No a n (%) Yes n (%) Odds Ratio* 1 st Trimester Only Any Malformations No Meds, No HTN 393,789 (94.6) 22,429 (5.4) Reference No Meds, With HTN 29,027 (92.8) 2,247 (7.2) 1.25 (1.19 – 1.31) Other Meds Only 1,062 (93.1) 79 (6.9) 1.22 (0.97 – 1.54) ACEI Any 393 (91.6) 36 (8.4) 1.19 (0.84 – 1.68) Congenital Heart Defects (CHD) No Meds, No HTN 393,789 (98.4) 6,232 (1.6) Reference No Meds, With HTN 29,027 (97.6) 708 (2.4) 1.41 (1.30 – 1.53) Other Meds Only 1,062 (97.4) 28 (2.6) 1.52 (1.04 – 2.21) ACEI Any 393 (96.1) 16 (3.9) 1.52 (0.91 – 2.55) Neural Tube Defects (NTD) No Meds, No HTN 393,789 (99.4) 2,447 (0.6) Reference No Meds, With HTN 29,027 (99.0) 281 (1.0) 1.43 (1.26 – 1.62) Other Meds Only 1,062 (99.2) 9 (0.8) 1.26 (0.65 – 2.44) ACEI Any 393 (99.5) 2 (0.5) 0.55 (0.14 – 2.23)

Table 2. Fetal Exposure to Antihypertensive Medications and the Risk of Major Malformations, Kaiser Permanente, Northern California (Cont.) Medication Use Birth Defects No a n (%) Yes n (%) Odds Ratio* Other Periods During Pregnancy 1 st Trimester Ever Any Malformations No Meds, No HTN 393,789 (94.6) 22,429 (5.4) Reference No Meds, With HTN 29,027 (92.8) 2,247 (7.2) 1.25 (1.20 – 1.31) Other Meds Only 4,063 (92.6) 327 (7.5) 1.29 (1.15 – 1.45) ACEI Any 701 (92.1) 60 (7.9) 1.10 (0.83 – 1.44) Congenital Heart Defects (CHD) No Meds, No HTN 393,789 (98.4) 6,232 (1.6) Reference No Meds, With HTN 29,027 (97.6) 708 (2.4) 1.41 (1.31 – 1.53) Other Meds Only 4,063 (97.1) 123 (2.9) 1.67 (1.39 – 2.01) ACEI Any 701 (96.6) 25 (3.4) 1.33 (0.87 – 2.02) Neural Tube Defects (NTD) No Meds, No HTN 393,789 (99.4) 2,447 (0.6) Reference No Meds, With HTN 29,027 (99.0) 281 (1.0) 1.44 (1.27 – 1.63) Other Meds Only 4,063 (99.0) 41 (1.0) 1.46 (1.07 – 2.00) ACEI Any 701 (99.2) 6 (0.9) 0.95 (0.42 – 2.17)

Table 2. Fetal Exposure to Antihypertensive Medications and the Risk of Major Malformations, Kaiser Permanente, Northern California (Cont.) Medication Use Birth Defects No a n(%) Yes n (%) Odds Ratio* Other Periods During Pregnancy 2 nd /3 rd Trimester Only Any Malformations No Meds, No HTN 393,789 (94.6) 22,429 (5.4) Reference No Meds, With HTN 29,027 (92.8) 2,247 (7.2) 1.26 (1.20 – 1.31) Other Meds Only 11,783 (89.8) 1,334 (10.2) 1.94 (1.83 – 2.05) ACEI Any 48 (85.7) 8 (14.3) 2.51 (1.18 – 5.34) Congenital Heart Defects (CHD) No Meds, No HTN 393,789 (98.4) ) 6,232 (1.6) Reference No Meds, With HTN 29,027 (97.6) 708 (2.4) 1.42 (1.31 – 1.54) Other Meds Only 11,783 (95.4) 566 (4.6) 2.90 (2.65 – 3.16) ACEI Any 48 (90.6) 5 (9.4) 5.03 (1.99 – 12.74) Neural Tube Defects (NTD) No Meds, No HTN 393,789 (99.4) 2,447 (0.6) Reference No Meds, With HTN 29,027 (99.0) 281 (1.0) 1.44 (1.27 – 1.63) Other Meds Only 11,783 (98.4) 193 (1.6) 2.51 (2.16 – 2.91) ACEI Any 48 (96.0) 2 (4.0) 5.05 (1.22 – 20.94) * Adjusted for preexisting diabetes, maternal age, race/ethnicity, parity and maternal weight. a. No any birth defect b. Anti-hypertensive medications c. Hypertension

Table 3. Fetal Exposure to Antihypertensive Medications and the Risk of Major Malformations, Among Mothers without Preexisting Diabetes, Kaiser Permanente Northern California Medication Use Birth Defects No a n (%) Yes n (%) Odds Ratio* 1 st Trimester Only Any Malformations No Meds b, No HTN c 392,290 (94.6) 222,77 (5.4) Reference No Meds, With HTN 28,423 (92.9) 2,162 (7.1) 1.25 (1.19 – 1.31) Other Meds Only 1,037 (93.3) 74 (6.7) 1.20 (0.94 – 1.52) ACEI Any 251 (94.4) 15 (5.6) 1.00 (0.59 – 1.68) Congenital Heart Defects (CHD) No Meds, No HTN 392,290 (98.5) 6,170 (1.6) Reference No Meds, With HTN 28,423 (97.7) 669 (2.3) 1.40 (1.29 – 1.52) Other Meds Only 1,037 (97.6) 26 (2.5) 1.50 (1.01 – 2.21) ACEI Any 251 (96.9) 8 (3.1) 1.85 (0.91 – 3.74) Neural Tube Defects (NTD) No Meds, No HTN 392,290 (99.4) 2,425 (0.6) Reference No Meds, With HTN 28,423 (99.1) 268 (0.9) 1.43 (1.26 – 1.62) Other Meds Only 1,037 (99.1) 9 (0.9) 1.33 (0.69 – 2.57) ACEI Any 251 (99.2) 2 (0.8) 1.20 (0.30 – 4.85)

Table 3. Fetal Exposure to Antihypertensive Medications and the Risk of Major Malformations, Among Mothers without Preexisting Diabetes, Kaiser Permanente Northern California (Cont.) Medication Use Birth Defects No a n (%) Yes n (%) Odds Ratio* Other Periods During Pregnancy 1 st Trimester Ever Any Malformations No Meds, No HTN 392,290 (94.6) 222,77 (5.4) Reference No Meds, With HTN 28,423 (92.9) 2,162 (7.1) 1.25 (1.19 – 1.31) Other Meds Only 3,890 (92.7) 308 (7.3) 1.31 (1.16 – 1.47) ACEI Any 429 (94.5) 25 (5.5) 0.98 (0.65 – 1.46) Congenital Heart Defects (CHD) No Meds, No HTN 392,290 (98.5) 6,170 (1.6) Reference No Meds, With HTN 28,423 (97.7) 669 (2.3) 1.41 (1.30 – 1.53) Other Meds Only 3,890 (97.1) 116 (2.9) 1.75 (1.45 – 2.11) ACEI Any 429 (97.3) 12 (2.7) 1.61 (0.90 – 2.86) Neural Tube Defects (NTD) No Meds, No HTN 392,290 (99.4) 2,425 (0.6) Reference No Meds, With HTN 28,423 (99.1) 268 (0.9) 1.43 (1.26 – 1.63) Other Meds Only 3,890 (99.0) 40 (1.0) 1.55 (1.13 – 2.13) ACEI Any 429 (98.6) 6 (1.4) 2.09 (0.93 – 4.69)

Table 3. Fetal Exposure to Antihypertensive Medications and the Risk of Major Malformations, Among Mothers without Preexisting Diabetes, Kaiser Permanente Northern California (Cont.) Medication Use Birth Defects No a n (%) Yes n (%) Odds Ratio* Other Periods During Pregnancy 2 nd /3 rd Trimester Only Any Malformations No Meds, No HTN 392,290 (94.6) 222,77 (5.4) Reference No Meds, With HTN 28,423 (92.9) 2,162 (7.1) 1.25 (1.19 – 1.31) Other Meds Only 11,540 (89.9) 1,299 (10.1) 1.95 (1.84 – 2.07) ACEI Any 40 (85.1) 7 (14.9) 2.98 (1.33 – 6.65) Congenital Heart Defects (CHD) No Meds, No HTN 392,290 (98.5) 6,170 (1.6) Reference No Meds, With HTN 28,423 (97.7) 669 (2.3) 1.41 (1.30 – 1.53) Other Meds Only 11,540 (95.5) 549 (4.5) 2.95 (2.70 – 3.23) ACEI Any 40 (88.9) 5 (11.1) 7.24 (2.85 – 18.36) Neural Tube Defects (NTD) No Meds, No HTN 392,290 (99.4) 2,425 (0.6) Reference No Meds, With HTN 28,423 (99.1) 268 (0.9) 1.43 (1.26 – 1.63) Other Meds Only 11,540 (98.4) 185 (1.6) 2.52 (2.17 – 2.93) ACEI Any 40 (95.2) 2 (4.8) 2 (4.8) 7.18 (1.73 – 29.80) * Adjusted for preexisting diabetes, maternal age, race/ethnicity, parity and maternal weight. a. No any birth defect b. Anti-hypertensive medications c. Hypertension

Table 4. Fetal Exposure to Antihypertensive Medications and the Risk of Major Malformations, among Mothers without Preexisting Diabetes, by an underlying diagnosis of hypertension, Kaiser Permanente, Northern California Medication Use Birth Defects No a n (%) Yes n (%) Odds Ratio* 1 st Trimester Only Any Malformations No Meds, No HTN 392,290 (94.6) 22,277 (5.4) Reference No Meds, With HTN 28,423 (92.9) 2,162 (7.1) 1.25 (1.19 – 1.31) Other Meds Only, No HTN 680 (92.8) 53 (7.2) 1.32 (1.00 – 1.75) Other Meds Only, With HTN 357 (94.4) 21 (5.6) 0.96 (0.62 – 1.50) ACEI Any, No HTN 22 (100.0) 0 (0.0) NA ACEI Any, With HTN 229 (93.9) 15 (6.2) 1.08 (0.64 – 1.83) Congenital Heart Defects (CHD) No Meds, No HTN 392,290 (98.5) 6,170 (1.6) Reference No Meds, With HTN 28,423 (97.7) 669 (2.3) 1.40 (1.29 – 1.52) Other Meds Only, No HTN 680 (97.6) 17 (2.4) 1.53 (0.95 – 2.48) Other Meds Only, With HTN 357 (97.5) 9 (2.5) 1.43 (0.74 – 2.78) ACEI Any, No HTN 22 (100.0) 0 (0.0) NA ACEI Any, With HTN 229 (96.6) 8 (3.4) 2.00 (0.99 – 4.06)

Table 4. Fetal Exposure to Antihypertensive Medications and the Risk of Major Malformations, among Mothers without Preexisting Diabetes, by an underlying diagnosis of hypertension, Kaiser Permanente, Northern California (Cont.) Medication Use Birth Defects No a n (%) Yes n (%) Odds Ratio* 1 st Trimester Only Neural Tube Defects (NTD) No Meds, No HTN 392,290 (99.4) 2,425 (0.6) Reference No Meds, With HTN 28,423 (99.1) 268 (0.9) 1.43 (1.26 – 1.62) Other Meds Only, No HTN 680 (99.3) 5 (0.7) 1.15 ( ) Other Meds Only, With HTN 357 (98.9) 4 (1.1) 1.66 (0.62 – 4.46) ACEI Any, No HTN 22 (100.0) 0 (0.0) NA ACEI Any, With HTN 229 (99.1) 2 (0.9) 1.31 (0.33 – 5.28) * Adjusted for maternal age, race/ethnicity, parity and maternal weight a. No any birth defect b. Anti-hypertensive medications c. Hypertension

Limitations Low frequency of ACEI use during pregnancy No information on compliance Limited information on confounders Inability to study individual defects

Strengths Large study population (almost a half million maternal-infant pairs) Population-based (every live-birth) Control for underlying indication (hypertension) Three types of controls

Confirmation from other studies Swedish study –A cohort study –Both ACEI and other antihypertensive medications had similarly increased risk of BDs CDC study –A case-control study –A similar association for both ACEI and other antihypertensive medications –Hypertension also increases the risk

Conclusions Maternal ACEI use in the first trimester has a risk profile similar to the use of other antihypertensive medications regarding malformations in live-born offspring Maternal ACEI use in the first trimester has a risk profile similar to underlying hypertension

Conclusions The apparent increased risk of malformations associated with ACEI use (and use of other antihypertensive medications) in the first trimester is likely due to the underlying hypertension rather than the medications

Important issues in drug safety research Unlikely to do RCT type studies –Ethical consideration Pregnancy –Effect on mother –Effect on fetus Example: antidepressants to PPD –Long-term safety issues

Important issues in drug safety research Observational studies –Based on existing automated data Claim data Clinical data EMR –Collect original data Cohort studies: –Expensive –Long-term follow up Case-control studies –Efficient –Recall issue (errors or biases)

Important issues in drug safety research Issues related to studies using automated data Control underlying indication: separate controls Incomplete ascertainment of exposed women –Drug coverage (outside the system) –Mixed in other drug categories –Sample size issue when exposure is rare, misclassified as non-user, rather than bias Compliance: can be a problem for rare drug exposure (dilute exposed group) depending on seriousness of underlying conditions.

Important issues in drug safety research Issues related to studies using automated data Limited information on confounders Potential biased ascertainment of conditions with significant under-diagnosis (e.g., depression, ADHD, etc.), users being examined more carefully Issues related to studies collecting original data –Same principles for cohort and case-control studies –Key: select correct controls.